Eckert & Ziegler: Development in the First Quarter of 2003 on Schedule
Berlin, 13.05.2003. Eckert & Ziegler AG, a specialist in medical and industrial isotope applications, was able to increase its result before tax and SFAS changes by over 70%, to 0.6 million EUR in the first quarter of 2003. These earnings include profits from the sale of a highly automated production plant and the US prostate seed business to the Theragenics Corp.
Total turnover dropped to 6.8 million EUR from the previous year 8.1 million EUR (nominally, off by almost 16%; adjusted to account for dollar fluctuations in the market, however, the drop was really less than 4%). While sales in the Cardiology division declined, as expected, to a quarter of last year value and remained stable in the area of Nuclear Imaging, the Industrial Sources and Oncology divisions were able to record double-digit rates of increase, with +10% and 15%, respectively. In view of these results as well as the positive development in the current quarter, the Board of Directors reaffirms its forecast of a result of 0.30 EUR per share for the entire year 2003. The Board of Directors
For further information please contact: Karolin Riehle Investor Relations Eckert & Ziegler AG Robert-Rössle-Strasse 10 D - 13125 Berlin http://www.ezag.com Tel.: +49 (0) 30 / 94 10 84-138 Fax.:+49 (0) 30 / 94 10 84-112 end of ad-hoc-announcement (c)DGAP 13.05.2003 --------------------------------------------------------------------------------
WKN: 565970; ISIN: DE0005659700; Index: Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, Hannover und Stuttgart 130744 Mai 03
Total turnover dropped to 6.8 million EUR from the previous year 8.1 million EUR (nominally, off by almost 16%; adjusted to account for dollar fluctuations in the market, however, the drop was really less than 4%). While sales in the Cardiology division declined, as expected, to a quarter of last year value and remained stable in the area of Nuclear Imaging, the Industrial Sources and Oncology divisions were able to record double-digit rates of increase, with +10% and 15%, respectively. In view of these results as well as the positive development in the current quarter, the Board of Directors reaffirms its forecast of a result of 0.30 EUR per share for the entire year 2003. The Board of Directors
For further information please contact: Karolin Riehle Investor Relations Eckert & Ziegler AG Robert-Rössle-Strasse 10 D - 13125 Berlin http://www.ezag.com Tel.: +49 (0) 30 / 94 10 84-138 Fax.:+49 (0) 30 / 94 10 84-112 end of ad-hoc-announcement (c)DGAP 13.05.2003 --------------------------------------------------------------------------------
WKN: 565970; ISIN: DE0005659700; Index: Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, Hannover und Stuttgart 130744 Mai 03